Search for:
Search for:
Healthcare Professionals
Publications
News
EspaƱol
Contact
Magazine
Radio
Get Educated
What is MS?
A chronic neurological disorder that affects the central nervous system, comprised of the brain...
More Details
Educational Materials
Common Questions
Lending Library
Symptoms
Treatment Options
Additional Resources
Research
MS Awareness Month
Donate
Get Help
Health & Wellness Program
Get educational materials and referrals, as well as the opportunity to participate in various...
Learn More
Grants & Programs
Awareness Campaigns
Support Groups
Events
Lending Library
Additional Resources
Get Involved
MS Awareness Month
An annual, nationwide campaign with goals to promote an understanding of MS, and to assist those...
Learn More
Advocacy
Buy from Partners
Volunteer
Businesses
MS Research Trials
Outreach
Awareness Campaigns
Host an Event
Events
Test Flyout
lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem...
Learn More
Events Calendar
Health & Wellness
Fundraisers
Support
Web & Teleconferences
MS Education
Host an Event
About Us
Programs & Grants
More Details
Overview
Press Room
Leadership
Financial Statements
Our Mission
Careers at MS Focus
Affiliations
News & Features
MS Focus At Sea
MS Focus At Sea offers educational programs, opportunities to meet old and new friends, and adventures for every...
/Events/MSF-Events/MSFocus-Cruise-For-A-Cause
Cooling Program
The Cooling Program offers a variety of items, free of charge, to help individuals with MS...
/Get-Help/MSF-Programs-Grants/Cooling-Program
Shop
Privacy
Terms of Use
Site Map
Disappearing lesions may predict disability development
June 06, 2018
For decades, clinicians treating multiple sclerosis have interpreted the appearance of new or expanding brain lesions on MRI scans as a sign that a patient's disease is getting worse. Now, after conducting both a five-year study, and a 10-year study, MS researchers in the Jacobs School of Medicine and Biomedical Sciences at University at Buffalo are finding that it may be the atrophy or disappearance of these lesions into cerebrospinal fluid that is a better indicator of who will develop disability.
Brain lesions in general are a sign of damage to the brain, such as physical trauma, a stroke, normal aging, or chronic disease. People with MS receive MRI scans as part of their routine care so doctors can track the appearance of new lesions and the enlargement of existing ones, typically seen as indicators of disease progression. The researchers noted that according to this premise, the loss of brain lesions could inadvertently be seen as a sign that the patient's condition is improving.
In order to focus specifically on the disappearance of lesions that likely indicate pathological change like atrophy, not beneficial change, like resolution or remyelination, the researchers looked exclusively at lesions seen on previous scans that were later replaced by cerebrospinal fluid. The researchers looked specifically at the rate of brain lesion loss because of atrophy compared to accumulation of lesion volume seen both at baseline and follow-up. They found that the amount of lesion volume that atrophied was the only significant lesion parameter that correlated with clinical disability as measured by the Expanded Disability Status Scale.
Researchers didn't find a link between people who developed more or larger lesions and developed increased disability, but they did find that atrophy of lesion volume predicted the development of more physical disability. While patients with relapsing remitting MS showed the highest amount of new lesions during the study, patients with progressive MS had the most accelerated volume of brain lesion atrophy. The researchers said this indicates that this new imaging biomarker could be particularly important in transitional phases between relapsing and progressive MS subtypes.
Another important finding of the studies is that atrophied brain lesions were shown to be a more robust predictor of disability progression than the development of whole brain atrophy itself, the most accepted biomarker of neurodegeneration in MS.
The five-year study was published in the
Journal of Neuroimaging
. The findings from the 10-year study were presented at the annual meeting of the American Academy of Neurology in Los Angeles in April.
MS Focus Lending Library
Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more